# Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors

> **NCT00569257** · PHASE2 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 85 (actual)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** AEZS-108

## Key facts

- **NCT ID:** NCT00569257
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2011-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569257, "Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00569257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*